Intensity Therapeutics/$INTS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Intensity Therapeutics
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
- Ticker
- $INTS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Shelton, United States
- Website
- intensitytherapeutics.com
INTS Metrics
BasicAdvanced
$10M
-
-$4.44
-
-
Price and volume
Market cap
$10M
52-week high
$8.06
52-week low
$2.80
Average daily volume
20K
Financial strength
Current ratio
3.68
Quick ratio
3.29
Long term debt to equity
0.007
Total debt to equity
0.011
Profitability
Management effectiveness
Return on assets (TTM)
-77.83%
Return on equity (TTM)
-161.84%
Valuation
Price to book
1.33
Price to tangible book (TTM)
1.33
Price to free cash flow (TTM)
-0.923
Free cash flow yield (TTM)
-108.32%
Free cash flow per share (TTM)
-3.347
Growth
Earnings per share change (TTM)
-65.24%
3-year earnings per share growth (CAGR)
-52.82%
What the Analysts think about INTS
Analyst ratings (Buy, Hold, Sell) for Intensity Therapeutics stock.
Analyst projections of the future price of Intensity Therapeutics stock.
INTS Financial Performance
Revenues and expenses
INTS Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.